Andrew Schwab Sells 45,147 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

Posted by Geri Gentry on Aug 23rd, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) Director Andrew Schwab sold 45,147 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $4.76, for a total value of $214,899.72. Following the sale, the director owned 2,579,998 shares of the company’s stock, valued at $12,280,790.48. This trade represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

CAMP4 Therapeutics Price Performance

Shares of CAMP stock opened at $4.48 on Friday. The stock’s 50-day moving average is $4.12 and its 200 day moving average is $4.34. CAMP4 Therapeutics Corporation has a 1-year low of $1.41 and a 1-year high of $7.75. The company has a market cap of $281.12 million, a P/E ratio of -1.93 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last announced its earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. On average, analysts anticipate that CAMP4 Therapeutics Corporation will post -0.57 EPS for the current year.

Wall Street Analyst Weigh In

CAMP has been the subject of a number of analyst reports. Chardan Capital set a $6.50 target price on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Zacks Research raised shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Finally, Weiss Ratings upgraded CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.56.

Get Our Latest Stock Report on CAMP

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE acquired a new position in CAMP4 Therapeutics during the fourth quarter valued at $86,000. Bridgeway Capital Management LLC acquired a new stake in CAMP4 Therapeutics during the 2nd quarter worth about $36,000. Two Sigma Investments LP acquired a new stake in CAMP4 Therapeutics during the 3rd quarter worth about $292,000. Vivo Capital LLC purchased a new position in shares of CAMP4 Therapeutics during the 3rd quarter valued at about $11,765,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of CAMP4 Therapeutics during the 4th quarter valued at about $61,000.

CAMP4 Therapeutics Company Profile

(Get Free Report)

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.